TC Biopharm Stock Scheduled to Reverse Split on Monday, February 10th (NASDAQ:TCBP)

Shares of TC Biopharm (Holdings) Plc (NASDAQ:TCBP) are set to reverse split before the market opens on Monday, February 10th. The 1-20 reverse split was announced on Wednesday, February 5th. The number of shares owned by shareholders will be adjusted after the market closes on Friday, February 7th.

TC Biopharm Price Performance

Shares of NASDAQ TCBP opened at $0.25 on Thursday. TC Biopharm has a 52-week low of $0.21 and a 52-week high of $26.16. The business’s 50 day moving average is $0.43 and its two-hundred day moving average is $2.40.

Analyst Upgrades and Downgrades

Separately, HC Wainwright cut their target price on TC Biopharm from $5.60 to $2.40 and set a “buy” rating on the stock in a research report on Friday, December 6th.

About TC Biopharm

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers.